Melanotan II (10 mg Vial) Dosage Protocol

Dosing & Reconstitution Overview

Melanotan II is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH) studied for its activity at the melanocortin receptors, principally MC1R and MC4R. The figures below are compiled strictly for laboratory and educational reference — they describe how the compound was handled and dosed across the published literature, not a recommendation for use in humans or animals.

For a 10 mg vial, adding 3.0 mL of bacteriostatic water yields a concentration of 3.33 mg/mL (3,333 mcg/mL). At that fill, a single unit drawn on a U-100 insulin syringe equals 0.01 mL and delivers roughly 33.3 mcg of material, which makes the small microgram steps in the titration straightforward to measure.

Standard (Gradual) Titration Schedule

The gradual schedule reflects the slow weekly dose-escalation approach reported in the literature, where the daily amount is stepped up across the first weeks to manage nausea and flushing while pigmentation develops.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until fully dissolved. Do not shake; aggressive agitation can shear the peptide.
4. The solution should be clear and colourless. Label the vial with the concentration (3.33 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw subsequent volumes with a fresh sterile syringe each time.

Loading & Maintenance Schedule

Because Melanotan II is studied as a daily-loading then intermittent-maintenance compound rather than a single fixed weekly dose, the published model splits the protocol into two distinct phases rather than a steadily climbing weekly arm.

Supplies Needed

• Melanotan II vials (10 mg): ~5 vials cover a full 6–8 week loading phase plus early maintenance (~45–50 mg total).
• Insulin syringes (U-100, 1 mL, 29–31 g): roughly 56 for a daily 8-week loading run (one fresh syringe per draw).
• Bacteriostatic water (10 mL): ~15 mL total (two bottles) reconstitutes several vials across the protocol.
• Alcohol swabs: ~112 swabs (two 100-count boxes) comfortably cover an 8-week daily schedule.

Protocol Overview

• Research goal: model UV-independent melanogenesis via melanocortin receptor (MC1R) activation.
• Schedule: daily subcutaneous loading, then 1–2× weekly maintenance in the published model.
• Dose band: 250–1000 mcg daily during loading; 500–1000 mcg per maintenance dose.
• Fill: 10 mg lyophilized, reconstituted to 3.33 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 250 mcg step and raise the daily amount weekly only once tolerability holds.
• Nausea and flushing tend to track the dose, so slower escalation is associated with smoother handling.
• Hold the 1000 mcg loading dose through Weeks 4–8 before stepping down to intermittent maintenance.
• Maintenance frequency is dialed to sustain the response rather than continue increasing it.

Storage Instructions

Keep sealed lyophilized vials at −20 °C (or below), protected from light and moisture, where stability extends for many months. Once reconstituted with bacteriostatic water, refrigerate at 2–8 °C and use within about one to two weeks. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and never expose the solution to prolonged heat or direct light.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Keep the stopper intact and swab it before each entry to preserve sterility.
• Measure the small microgram volumes carefully, since at 3.33 mg/mL a few units shift the dose meaningfully.
• Document each draw — date, volume, remaining material — for reproducibility.

How Melanotan II Works

Melanotan II is a synthetic cyclic heptapeptide modeled on α-melanocyte-stimulating hormone. It binds and activates the melanocortin receptors, most notably MC1R on melanocytes and MC4R in the central nervous system. Activation of MC1R drives melanin (eumelanin) synthesis independently of ultraviolet exposure, which underlies its studied pigment-darkening effect. Its cyclic structure and amino-acid substitutions give it greater receptor potency and a longer duration than native α-MSH. Activity at MC4R is associated with the appetite and libido effects observed alongside pigmentation in the literature.

Reported Benefits & Side Effects

Effects observed in studies

• Increased skin pigmentation without requiring ultraviolet exposure.
• Visible darkening typically reported after roughly 5–10 daily administrations.
• Reduced appetite, attributed to central MC4R activity.
• Spontaneous erectile and libido effects in male subjects, also linked to MC4R.

Side effects reported

• Dose-dependent nausea, facial flushing and a sensation of skin warmth, most common early in loading.
• Mild fatigue and injection-site reactions.
• Changes in the appearance or number of moles/freckles, warranting caution in the literature.
• Serious sympathomimetic reactions and a case of rhabdomyolysis were reported at higher exposures (around 6 mg); the compound is not approved by the FDA or other regulators.

Injection Technique (Reference Only)

• Swab the vial stopper and the injection site with alcohol and let both air dry.
• Use a 1 mL U-100 insulin syringe (29–31 gauge, ½-inch needle) for subcutaneous administration.
• Pinch about an inch of skin — the abdomen, at least two inches from the navel, is a commonly cited site.
• Insert at a 45–90° angle and inject slowly; aspiration is not required for subcutaneous work.
• Rotate sites systematically to avoid lipohypertrophy, and dispose of sharps in an approved container — never reuse a needle.

References

Related Protocols